The Claim
No patient with homozygous familial hypercholesterolemia (HoFH) achieved the European Atherosclerosis Society (EAS)-recommended low-density lipoprotein cholesterol (LDL-C) targets when treated with PCSK9 inhibitors in combination with standard lipid-lowering therapies, including statins, ezetimibe, and, in some cases, lipid apheresis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Even when people with a rare genetic cholesterol disorder take powerful new drugs called PCSK9 inhibitors along with their usual treatments, none of them got their bad cholesterol down to the recommended healthy levels.
See the scientific wording
No patient with homozygous familial hypercholesterolemia (HoFH) achieved European Atherosclerosis Society (EAS)-recommended LDL-C targets while receiving PCSK9 inhibitors in addition to standard lipid-lowering therapy, including statins, ezetimibe, and in some cases lipid apheresis.
What the research says
1 studyThe study looked at patients with a rare cholesterol condition who were taking PCSK9 inhibitors along with other cholesterol drugs, and none of them got their cholesterol low enough to meet the recommended targets.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.